Predict your next investment

Corporation
HEALTHCARE | Medical Devices & Equipment / Surgical Devices
misonix.com

See what CB Insights has to offer

Portfolio Exits

1

Partners & Customers

5

About Misonix

Misonix specializes in the development and commercialization of ultrasonic surgical devices for neurosurgical, spinal, advanced wound care, and general surgery procedures. The company's portfolio of products is all based upon the unique properties of ultrasound and its ability to differentiate hard and soft tissue for different clinical requirements.On October 29th, 2021, Misonix was acquired by Bioventus at a valuation of $518M.

Misonix Headquarter Location

1938 New Highway

Farmingdale, New York, 11735,

United States

631-694-9555

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Misonix Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Misonix Rank

Latest Misonix News

Tumor Ablation Therapy Devices Global Market Report 2022

May 24, 2022

Major players in the tumor ablation therapy devices market are Galil Medical Inc, Misonix Inc, HealthTronics, Angiodynamics, Boston Scientific Corporation, Medtronic Plc, EDAP TMS S. A, Neuwave Medical Inc, BVM Medical Limited, and Erbe Elektromedizin GmbH. May 24, 2022 04:43 ET Lyon, FRANCE New York, May 24, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Tumor Ablation Therapy Devices Global Market Report 2022" - https://www.reportlinker.com/p06280915/?utm_source=GNW The global tumor ablation therapy devices market is expected to grow from $0.49 billion in 2021 to $0.56 billion in 2022 at a compound annual growth rate (CAGR) of 14.1%. The market is expected to grow to $0.97 billion in 2026 at a compound annual growth rate (CAGR) of 15%. The tumor ablation therapy devices market consists of sales of tumor ablation devices and related services that are used in hospitals and oncology clinics. Tumor ablation is the technique used to extract the tumors using a needle, to insert them in the tumor organ using imaging techniques. The main technologies in the tumor ablation therapy devices are radiofrequency ablation, microwave ablation, cryoablation, irreversible electroporation ablation, and others.Irreversible electroporation (IRE) in tumor ablation therapy is a new tissue ablation method in which micro to millisecond electrical pulses are supplied to undesirable tissue to produce cell necrosis by irreversible cell membrane permeabilization. The treatments included are surgical, laparoscopic, and percutaneous that are used in various applications such as kidney cancer, liver cancer, breast cancer, lung cancer, prostate cancer, and others. The various end-users of tumor ablation therapy devices are hospitals, oncology clinics, and others. North America was the largest region in the tumor ablation therapy devices market in 2021.Asia Pacific was the second largest region in the tumor ablation therapy devices market. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The increasing prevalence of cancer is a key factor driving the growth of the tumor ablation therapy devices market.Cancer is considered to be the second major cause of death, with around 1 in 6 deaths due to cancer worldwide. Tumor ablation is a minimally invasive procedure widely used in the treatment of lung, liver, kidney, and bone tumors. For instance, in 2020, according to the American Institute of cancer research, there were an estimated 18.1 million cancer cases around the world. It was estimated that 9.3 million cases were in men and 8.8 million in women. Among them, lung and breast cancers are the most common cancers in the world, and about 12.5% and 12.2% of the new cases are diagnosed in 2020. The procedure is an effective method for patients who have failed chemotherapy or radiotherapy, thereby supporting the growth of the tumor ablation therapy devices market. Product recalls of tumor ablation devices due to technical issues are expected to hinder the growth of the tumor ablation therapy devices market.The companies are retrieving their products from the market due to safety concerns. For instance, Covidien Emprint Long Percutaneous Antenna with Thermosphere Technology, a tumor ablation device from Medtronic had recalled its devices due to the disengagement of ceramic trocar tip of the Emprint ablation from the needle shaft post-ablation.Similarly, in June 2018, Accurian RF Ablation by Medtronic Sofamor Danek USA Inc was recalled due to the difficulty in insertion. The product recalls caused a financial burden on the companies hindering the tumor ablation therapy devices market. Major companies operating in the tumor ablation therapy devices are focusing on technology advancements for shorter procedures, increased safety, lower exposure to radiation, faster learning curves, and improved outcomes J&J medicals have released a microwave ablation system called NEUWAVE, which is the first minimally invasive device to put electrodes into cancer cells and thereby increase the temperature around them for burning the cancer cells. In June 2020, Boston Scientific has launched a technology called DirectSense technology, a tool used for monitoring the effect of radiofrequency (RF) now for cardiac procedures, which may be further employed for tumors. In June 2019, Varian Medical Systems acquired Endocare for an undisclosed amount.This acquisition will help Varian Medical Systems strengthen its portfolio by adding cryoablation and microwave ablation therapies and embolic beads to its cancer care solutions portfolio. Endocare is a leading provider of hardware and software solutions supporting cryoablation and microwave ablation. The countries covered in the tumor ablation therapy devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA.

Misonix Portfolio Exits

1 Portfolio Exit

Misonix has 1 portfolio exit. Their latest portfolio exit was Misonix - BoneScalpel Business on February 03, 2015.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

2/3/2015

Divestiture

1

Date

2/3/2015

Exit

Divestiture

Companies

Valuation

Acquirer

Sources

1

Misonix Acquisitions

1 Acquisition

Misonix acquired 1 company. Their latest acquisition was Solsys Medical on May 02, 2019.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

5/2/2019

Series B

$99M

$35.6M

Acquired

6

Date

5/2/2019

Investment Stage

Series B

Companies

Valuation

$99M

Total Funding

$35.6M

Note

Acquired

Sources

6

Misonix Partners & Customers

5 Partners and customers

Misonix has 5 strategic partners and customers. Misonix recently partnered with CryoLife on December 12, 2019.

Date

Type

Business Partner

Country

News Snippet

Sources

12/19/2019

Licensor

United States

CryoLife, Misonix sign distribution deal for NeoPatch

`` Misonix is the perfect partner to commercialize NeoPatch due to its knowledge and expertise in the wound care business , '' CryoLife CEO Pat Mackin said in a news release .

4

10/25/2017

Partner

United States

Subscribe to see more

Subscribe to see more

10

3/8/2017

Partner

China

Subscribe to see more

Subscribe to see more

10

8/11/2016

Partner

United States

Subscribe to see more

Subscribe to see more

10

4/2/2012

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

12/19/2019

10/25/2017

3/8/2017

8/11/2016

4/2/2012

Type

Licensor

Partner

Partner

Partner

Partner

Business Partner

Country

United States

United States

China

United States

United States

News Snippet

CryoLife, Misonix sign distribution deal for NeoPatch

`` Misonix is the perfect partner to commercialize NeoPatch due to its knowledge and expertise in the wound care business , '' CryoLife CEO Pat Mackin said in a news release .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

4

10

10

10

10

You May Also Like

Nela Biodynamics Logo
Nela Biodynamics

Nela Biodynamics offers a novel modular system for intramedullary implants with a wide range of applications.

A
Advanced Osteotomy Tools

Advanced Osteotomy Tools is dedicated to the development, manufacturing and sales of medical devices for osteotomy, pursuing the vision of contact-free bone surgery using laser, robotics and navigation systems to re-invent bone surgery (osteotomy).

C
Crely

Crely develops a medical device-enabled software as a service platform to detect, predict and reduce surgical site infection rates after surgery, and to improve health outcomes and patient experience. It was founded in 2017 and is based in San Jose, California.

moveUP Logo
moveUP

MoveUP offers personalized digital care pathways in orthopedic and bariatric areas through a medical device and an app. MoveUP uses more than 400 data points as insights to propose a continuously adapting recovery therapy plan comprising of activities, medication, physical therapy exercises, and coaching.

Integra LifeSciences Logo
Integra LifeSciences

Integra LifeSciences (NSDQ: IART) manufactures specialty medical devices which include fiber optic headlights, light sources, cables, headlight video camera systems, surgical telescopes, and more for applications in orthopedic extremity surgery, neurosurgery, spine surgery, and reconstructive and general surgery.

Depuy Synthes Logo
Depuy Synthes

Depuy Synthes offers a portfolio of orthopedic and neuro products and services for joint reconstruction, trauma, spine, sports medicine, neuro, craniomaxillofacial, power tools and biomaterials.Acquired by Johnson & Johnson in 1998, its companies form part of the Johnson & Johnson Medical Devices group. DePuy develops and markets products under the Codman, DePuy Mitek, DePuy Orthopaedics and DePuy Spine brands.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.